The case in brief

This is an invented teaching case adapted from a synthetic assessment narrative. It is not a patient record or a live MontMedical consultation.

A person has early-onset granulomatous colitis, perianal disease and recurrent superficial staphylococcal infections. Repeated neutrophil testing after PMA stimulation gives DHR fluorescence of 95–104% of control. However, neutrophil killing of ingested Staphylococcus aureus is 22–29%, compared with 79–88% in controls.

Initial uptake, cell viability and the other supplied control measurements are comparable. Washed patient neutrophils remain impaired when given healthy serum, while control neutrophils function normally with the patient's serum. Two independently generated EBV-transformed B-cell lines produce only 8–12% of control extracellular superoxide after PMA. No causal genotype has been established, and neutrophil oxidant production during ingestion has not yet been measured.

What the experiments establish

Observation What it identifies What to investigate next
Repeated normal PMA-DHR in neutrophils Preserved measured oxidation under that stimulus A response relevant to bacterial ingestion
Poor intracellular S. aureus killing with normal uptake A defect in the supplied killing experiment after ingestion The mechanism responsible for impaired killing
Healthy serum does not correct patient cells A cell-associated contribution in this experimental comparison The cellular function that is impaired
Low B-cell superoxide in independent lines An abnormality in that cell type and assay Its relationship to the neutrophil and clinical phenotype

The controls are part of the evidence. They reduce specific alternative explanations, such as a simple difference in initial uptake or correction by a healthy serum factor. They do not turn the killing result into a direct measurement of phagosomal oxidant production.

Why p40phox is relevant

The NADPH oxidase system generates reactive oxygen species in phagocytes. The p40phox protein, encoded by NCF4, contributes to this system. A 2018 clinical and laboratory study described 24 people with inherited p40phox deficiency. Their particle-triggered neutrophil oxidase responses were impaired even when PMA-DHR oxidation was normal or only mildly impaired; oxidase activity in EBV-transformed B cells was also markedly reduced. [1]

That published pattern makes an NCF4-related defect a well-matched candidate here. The key principle is that the cell type, stimulus and compartment matter. A soluble-stimulus screening result and a response during particle ingestion are related experiments, but they are not the same measurement.

Keep the leading interpretation firm and specific

The combined clinical and laboratory pattern favours a variant oxidase disorder, particularly p40phox deficiency, over interpreting the colitis alone as an isolated idiopathic bowel disease. That is a provisional synthesis of the supplied observations and the published precedent.

The unresolved mechanism should be named precisely. The killing assay demonstrates impaired killing in this experiment. It has not directly demonstrated reduced oxidant production during ingestion. A relevant particulate-stimulus assay would address that question; molecular testing would address the suspected inherited cause.

This is a stronger explanation than saying only that “more testing is needed.” It identifies which test answers which question.

Why the prognosis does not transfer automatically

The p40phox study reported a clinical pattern different from classic chronic granulomatous disease, with peripheral infections and hyperinflammation and without the invasive infections observed in classic CGD in that cohort. This is evidence about the reported patients, not proof of zero future infection risk for every person with an NCF4 defect. [1]

The practical lesson is to distinguish recognising an oxidase disorder from importing every prognostic or treatment assumption attached to another subtype. Individual assessment belongs with the clinical team and the confirmed phenotype and genotype.

The next discriminating questions

Does oxidant production fall when these neutrophils ingest an appropriate particle or organism? Does genetic analysis identify a causal variant consistent with the functional and family findings? Do the results support the same explanation across the different cell types?

Those questions preserve the value of the existing experiments. They neither discard the normal screening result nor ask it to answer a question it did not measure.

How to use this example with MontMedical

This is an editorial teaching analysis, not a preserved live product output or an independent performance score. It illustrates the reasoning to look for when reviewing a MontMedical answer: a clear leading explanation, an account of the controls and a specific next discriminator.

MontMedical provides case discussions and referenced evidence reviews. Explore a clinical case or return to the guide on interpreting a normal result. Check the original sources and discuss individual testing or treatment decisions with the relevant clinician.